首页> Pharmacological reports : PR> Post-marketing surveillance study on the effectiveness and safety of molnupiravir in high-risk COVID-19 outpatients: a prospective case series study.

Post-marketing surveillance study on the effectiveness and safety of molnupiravir in high-risk COVID-19 outpatients: a prospective case series study.

导出 LinkOut

翻译打印收藏纠错

第一作者： Renato,Ferreira-da-Silva

第一单位： Porto Pharmacovigilance Centre, Faculty of Medicine of the University of Porto, Porto, Portugal. renato.ivos@gmail.com.;Department of Community Medicine, Information and Health Decision Sciences (MEDCIDS), Faculty of Medicine of the University of Porto, Porto, Portugal. renato.ivos@gmail.com.;RISE-Health, Porto, Portugal. renato.ivos@gmail.com.

作者： Renato,Ferreira-da-Silva ^[1] ; Lurdes,Silva ^[2] ; Cristina,Costa-Santos ^[3] ; Manuela,Morato ^[4] ; Jorge Junqueira,Polónia ^[5] ; Inês,Ribeiro-Vaz ^[6] ; Manuela,Pinto ^[7] ; Marta,Pereira ^[8] ; Inês Marques,Figueira ^[9] ; Sofia,Baptista ^[10] ; Helena,Farinha ^[11] ; Fátima,Falcão ^[11] ; Ana,Mirco ^[11] ; Liliana,Calixto ^[11] ; Madalena,Melo ^[12] ; ESOA-19 Research Team

作者单位： Porto Pharmacovigilance Centre, Faculty of Medicine of the University of Porto, Porto, Portugal. renato.ivos@gmail.com.;Department of Community Medicine, Information and Health Decision Sciences (MEDCIDS), Faculty of Medicine of the University of Porto, Porto, Portugal. renato.ivos@gmail.com.;RISE-Health, Porto, Portugal. renato.ivos@gmail.com. ^[1] Porto Pharmacovigilance Centre, Faculty of Medicine of the University of Porto, Porto, Portugal. ^[2] Department of Community Medicine, Information and Health Decision Sciences (MEDCIDS), Faculty of Medicine of the University of Porto, Porto, Portugal.;RISE-Health, Porto, Portugal. ^[3] Laboratory of Pharmacology, Department of Drug Sciences, Faculty of Pharmacy of the University of Porto, Porto, Portugal.;LAQV@REQUIMTE, Faculty of Pharmacy of the University of Porto, Porto, Portugal. ^[4] Porto Pharmacovigilance Centre, Faculty of Medicine of the University of Porto, Porto, Portugal.;Department of Medicine, Faculty of Medicine of the University of Porto, Porto, Portugal. ^[5] Porto Pharmacovigilance Centre, Faculty of Medicine of the University of Porto, Porto, Portugal.;Department of Community Medicine, Information and Health Decision Sciences (MEDCIDS), Faculty of Medicine of the University of Porto, Porto, Portugal.;RISE-Health, Porto, Portugal. ^[6] Local Health Unit of São João, EPE, Porto, Portugal. ^[7] Local Health Unit of Santo António, EPE, Porto, Portugal. ^[8] Local Health Unit of Vila Nova de Gaia/Espinho, EPE, Vila Nova de Gaia, Portugal. ^[9] Department of Community Medicine, Information and Health Decision Sciences (MEDCIDS), Faculty of Medicine of the University of Porto, Porto, Portugal.;RISE-Health, Porto, Portugal.;Family Health Unit - Homem do Leme (ACES Porto Ocidental), Porto, Portugal. ^[10] Local Health Unit of Lisboa Ocidental, EPE, Lisboa, Portugal. ^[11] Divino Espírito Santo Hospital - Ponta Delgada, EPE, Azores, Portugal. ^[12]

关键词 Adverse drug events Antiviral agents COVID-19 drug treatment Molnupiravir Post-marketing surveillance SARS-CoV-2